The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]
Eric Siemers, MD
Advertisement
Chief medical officer at Acumen Pharmaceuticals.
Articles by Eric Siemers, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Building the Foundation for Earlier Alzheimer Disease Diagnosis
5